A small clinical trial of 10 patients with early Alzheimer’s disease has shown that the memory loss and cognitive impairment can be reversed.
Not only were improvements sustained, but some patients returned to work, regained their ability to speak different languages, and showed an increase in brain matter volume after just a few months.
“All of these patients had either well-defined mild cognitive impairment, subjective cognitive impairment, or had been diagnosed with Alzheimer’s disease before beginning the program,” says one of the team, Dale Bredesen, University of California, Los Angeles. “Follow up testing showed some of the patients going from abnormal to normal.”
The study investigated the effects of a new kind of personalised treatment on the cognitive abilities of 10 patients who were experiencing age-related decline.
The treatment – called metabolic enhancement for neurodegeneration, or MEND – is based on 36 different factors, including changes in diet, exercise, and sleeping habits, plus the integration of certain drugs, vitamins, and brain stimulation therapy to their regular routine.
These lifestyle changes and treatments were sustained for five to 24 months, and the team from UCLA and the Buck Institute for Research on Ageing in California reports that many of the patients showed real, life-altering improvements as a result.
According to the researchers, this is the first study to objectively show that memory loss in patients can be reversed, and improvement sustained.
“The magnitude of improvement in these 10 patients is unprecedented, providing additional objective evidence that this programmatic approach to cognitive decline is highly effective,” says Bredesen.
Publishing their results in the journal Aging, the team hasn’t gone into much detail about how MEND works, probably because each treatment involves a complex combination of factors that has been specifically designed to treat just one individual, as each person’s version of Alzheimer’s appears to be different.
But they do mention something that all but one of the patients have in common – they are all at genetic risk for Alzheimer’s disease, carrying at least one copy of the APOE4 allele. Five of the patients are carrying two copies of APOE4, which gives them a 10- to 12-fold increased risk of developing the disease, the team explains.
This means there could be some benefit in getting tested for this genetic risk, because patients might finally be able to do something to stall the progression of the disease. Around 65 percent of Alzheimer’s cases in the US involve APOE4.
“We’re entering a new era,” says Bredesen. “The old advice was to avoid testing for APOE because there was nothing that could be done about it. Now we’re recommending that people find out their genetic status as early as possible so they can go on prevention.”
Learn more: Small trial shows memory loss from Alzheimer’s disease can be reversed
The Latest on: APOE4
[google_news title=”” keyword=”APOE4″ num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: APOE4
- A gene long thought to just raise the risk for Alzheimer's may cause some caseson May 24, 2024 at 5:00 pm
Scientists have long known a gene called APOE4 is one of many things that can increase people’s risk for Alzheimer’s, including simply getting older. The vast majority of Alzheimer’s cases occur after ...
- Researchers Identify New Genetic Form of Alzheimer’s Diseaseon May 24, 2024 at 6:49 am
Scientists have discovered that nearly all individuals with two copies of the APOE4 gene will develop signs of Alzheimer's disease, suggesting a distinct genetic form of Alzheimer's. In a new study ...
- Lifestyle-Dementia Links Persist Regardless of Risk Genes, French Study Showson May 23, 2024 at 3:52 pm
Across nearly 5,200 people in three French cities, worse scores on the Lifestyle for Brain (LIBRA) health risk scale at baseline were tied to both subsequent cognitive decline and dementia incidence, ...
- Lisa Jarvis: Would you get tested for an Alzheimer’s gene?on May 13, 2024 at 4:45 am
In a new paper in "Nature Medicine," an international team of neurologists makes the compelling case that people with two copies of a gene called APOE4 aren’t just at risk ...
- Study suggests two copies of APOE4 gene behind up to 20% of Alzheimer's caseson May 12, 2024 at 6:00 am
A team of neurologists affiliated with multiple institutions in Spain and the U.S. has found evidence that suggests up to 20% of all cases of Alzheimer's disease (AD) may be attributable to double ...
- Do Two APOE4 Alleles Always Mean Alzheimer's?on May 9, 2024 at 4:59 pm
For 30 years, APOE4 has ranked as the strongest genetic risk factor for Alzheimer’s disease, with two copies boosting the odds up to 15-fold. Now, scientists make the case that people with two APOE4 ...
- Almost All People With Two Copies of This Genetic Variant Develop Signs of Alzheimer's Disease, Study Findson May 7, 2024 at 1:56 pm
Almost all people with two copies of a genetic variant called APOE4 show signs of Alzheimer’s disease, according to a new study of people predominantly of European ancestry. The findings suggest that ...
- Genes known to increase the risk of Alzheimer’s may actually be an inherited form of the disorder, researchers sayon May 6, 2024 at 11:22 am
APOE3 is thought to confer a neutral risk of the disease. APOE4, on the other hand, is bad news. It has long been recognized that people with at least one copy of the APOE4 gene have an elevated ...
- A gene long thought to just raise the risk for Alzheimer’s may cause some caseson May 6, 2024 at 9:00 am
Scientists have long known a gene called APOE4 is one of many things that can increase people’s risk for Alzheimer’s, including simply getting older. The vast majority of Alzheimer’s cases ...
- Study identifies APOE4 homozygotes as high-risk group for Alzheimer's diseaseon May 5, 2024 at 5:00 pm
The study, published today in Nature Medicine, also concludes that those individuals homozygous for APOE4 also develop the disease earlier than those with other variants of the APOE gene.
via Bing News